FDA notified healthcare professionals of a newly published clinical study showing that patients treated with an erythropoiesis-stimulating agent (ESA) and dosed to a target hemoglobin concentration of 13.5 g/dL are at a significantly increased risk for serious and life threatening cardiovascular complications, as compared to use of the ESA to … [Read more...]
Search Results for: labeling
When Corporations can "Negotiate" with our Government Agencies on Dangerous Products…
On our Environmental Product Recall Page we recently alerted consumers to news about the potential danger of Hartz Flea and Tick Drops for Cats and Kittens. Among these dangers are worrisome issues like hair loss and increased salivation, as well as very serious problems like tremors and death. That's right - Death!This item of news mentioned that … [Read more...]
Paxil Birth Defects – FDA Releases Early Study Results
Announced on December 8, 2005Consumer Inquiries: 888-INFO-FDAThe Food and Drug Administration (FDA) has alerted health care professionals and patents who take Paxil about the preliminary results of a new Paxil ( Paroxetine ) study. The early findings suggest that Paxil increases the risk for birth defects, especially heart defects, when taken … [Read more...]
The Ortho Evra Contraceptive Patch Gets Updated Lebeling by FDA
The Ortho Evra Contraceptive Patch has been relabeled, in accordance with FDA regulation, to warn healthcare providers and patients that it exposes women to higher levels of estrogen than most oral birth control pills. Ortho Evra was the first birth control skin patch approved by the FDA. It is a weekly prescription patch that releases ethinyl … [Read more...]
Recent Comments